Fisher & Paykel share price slides hard following FY23 guidance update

Falling asx share price represented by surprised fat fishFalling asx share price represented by surprised fat fish

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price is struggling from the open on Friday following a company update.

At the time of writing, the Fisher & Paykel share price is trading 6% down at $17.98 after it announced its FY23 guidance.

Fisher & Paykel expects slow down in FY23

Detailing its forecasts for the coming 12 months, the healthcare giant said that it anticipates revenue of $670 million and net profit after tax (NPAT) of $85–$95 million.

This signifies an increase in revenue compared to 1H FY20’s $570.9 yet a decline in revenue compared to the prior comparable period, being 1H FY22 at $900 million.

CEO Lewis Gradon said the company had “sold approximately ten years’ worth of hardware in two years” creating a high comparison in FY22 as well.

“This does not change the fundamentals of our business or our strategy,” he added.

“Our Hospital sales teams are still focused on changing clinical practice and helping ensure the hardware our customers have purchased is used to benefit a broader range of patients requiring respiratory support.”

Gross margin for the first half is also expected to land at 60% – 500 basis points below the company’s long-term target of 65%.

Part of the contraction in gross profit is due to a shift in sales towards the lower margin consumables segment.

However, despite challenges, it expects that H2 FY23 revenue will be higher than the first half as hospitalisation rates normalize.

“The company is now targeting constant currency operating expense growth of approximately 10%
for the year,” it added.

Never before in our history have we changed clinical practice with such a significant advantage.
Our customers already have our hardware, they already have clinical experience with its use, and
they already have access to a huge amount of clinical evidence. This gives us confidence that we
can continue to build on our proven 50-year track record and reach more patients with our
respiratory therapies.

In the past 12 months, the Fisher & Paykel share price is down 44%, and down 41% this year to date.

The post Fisher & Paykel share price slides hard following FY23 guidance update appeared first on The Motley Fool Australia.

Should you invest $1,000 in Fisher & Paykel Healthcare Corp Ltd right now?

Before you consider Fisher & Paykel Healthcare Corp Ltd, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Fisher & Paykel Healthcare Corp Ltd wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

See The 5 Stocks
*Returns as of August 4 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/wIpX9U7

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *